Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 20 sources · 8 days · First seen about 1 month ago · Last updated 29 days ago

Redcare Pharmacy financial performance and guidance

Overview

Redcare Pharmacy has seen positive momentum driven by strong market performance and updated financial outlooks.

In late September, the company’s shares rose by 5.42 percent on the Xetra exchange, reaching 64.20 euros. This surge followed a ‘Buy’ rating from Deutsche Bank Research, which suggested that recent price weakness offered an attractive entry point and anticipated that upcoming third-quarter results would support the company’s annual guidance.

By the end of the month, Redcare Pharmacy raised its full-year 2026 revenue guidance for the second time in the year. The company expects German prescription medication revenue to grow by 45% to 51%, reaching between EUR 730 million and EUR 760 million. This is an increase from the previous guidance of EUR 680 million to EUR 720 million. Consequently, total group revenue growth guidance was adjusted upward to a range of 16%–18%.

CEO Olaf Heinrich attributed this growth to high customer satisfaction and the increasing adoption of electronic prescriptions, noting that the electronic prescription (e-Rx) Net Promoter Score rose to 80 points in August. While the prescription segment shows strong performance, the company maintained its guidance for non-Rx revenue growth at 10% to 12% and confirmed its adjusted EBITDA margin target of 2.5% to 3.0%.

Entities

Redcare Pharmacy · Vonovia · Levi Garraway · European Union · Dallas Fed

Claims

What the coverage asserts, and how many sources carry each claim.

[● 2 SOURCES] The Dallas Fed will release a report on manufacturing activity.
[● 2 SOURCES] A corruption trial involving former automotive executive Carlos Ghosn and former French minister Delphine Dati is expected to conclude.
[○ 1 SOURCE] Roche aims to bring 20 new, highly effective medicines to market by 2030.
[○ 1 SOURCE] Roche plans to redistribute approximately 2 billion Swiss francs within its research budget by the end of 2026.
[○ 1 SOURCE] The success rate for projects entering Phase III clinical development was 65 percent in 2025 and over 80 percent so far in 2026.
[○ 1 SOURCE] Roche participation certificates fell by 0.8 percent to 357.50 Swiss francs.
[○ 1 SOURCE] EU agriculture and fisheries ministers are meeting to discuss topics including drought.
[○ 1 SOURCE] TotalEnergies is holding an investor day.

Timeline

29 days ago

[BUSINESS] 19 sources
Global markets react to rising US yields and Redcare Pharmacy guidance hike
Global markets face volatility as rising US Treasury yields and Fed inflation policies strengthen the dollar, while the DAX remains resilient and Redcare Pharmacy raises its 2026 revenue guidance.
about 1 month ago

[BUSINESS] 2 sources
Redcare Pharmacy shares surge following positive Deutsche Bank analysis
Redcare Pharmacy shares rose 5.42 percent to 64.20 euros on Xetra, driven by a positive ‘Buy’ rating from Deutsche Bank Research following recent price weakness.

Sources

4investors.de · ad-hoc-news.de · ariva.de · berliner-sonntagsblatt.de · cash.ch · devdiscourse.com · finanzen.at · finanzen.net · finanznachrichten.de · g4media.ro · it-boltwise.de · klamm.de · mediafax.ro · moneycab.com · n-tv.de · newmediawire.com · newscentral.africa · oldenburger-onlinezeitung.de · plusvisionen.de · sharedeals.de

This summary has been updated 1 time: see revision history